Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
In many cases, children between the ages of 6 months and 8 years should receive 2 doses of the influenza vaccine separated by a minimum of 4 weeks.
A starter pack of Janssen Pharmaceuticals’ rivaroxaban (Xarelto) will be available at pharmacies starting in October 2014.
In a Phase 3 study, odanacatib significantly reduced the risk of osteoporotic fractures, but it also might have contributed to major cardiovascular events.
Latest Issues
$auto_registration$